Compare VREX & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VREX | ASMB |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 580.6M | 440.0M |
| IPO Year | 2016 | 2010 |
| Metric | VREX | ASMB |
|---|---|---|
| Price | $10.86 | $28.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $16.67 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 334.0K | 92.6K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $811,000,000.00 | N/A |
| Revenue This Year | $5.35 | $33.33 |
| Revenue Next Year | $3.88 | N/A |
| P/E Ratio | $225.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.76 | $7.76 |
| 52 Week High | $14.57 | $39.71 |
| Indicator | VREX | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 21.12 | 48.18 |
| Support Level | $10.81 | $26.50 |
| Resistance Level | $12.61 | $30.66 |
| Average True Range (ATR) | 0.43 | 1.46 |
| MACD | -0.27 | 0.04 |
| Stochastic Oscillator | 2.97 | 36.74 |
Varex Imaging Corp Designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, detectors, ionization chambers, high-voltage connectors, software, collimators, generators, exposure control devices, and heat exchangers.. The company operates through two segments: Medical, the key revenue driver, providing X-ray imaging components and accessories for healthcare applications, and Industrial, which provides Linatron X-ray accelerators, X-ray tubes, flat panel detectors, high-voltage connectors, and coolers for non-medical use. Geographically, it generates the majority of its revenue from Europe, the Middle East, and Africa (EMEA), with the rest coming from the Americas and Asia Pacific.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.